Post

Longboard reports positive data from Phase I LP352 clinical study

The trial findings showed that LP352 exhibited a strong correlation between plasma and CSF PK concentration.

Mirati reports initial data from lung cancer trials

Grade 1-2, Grade 3, and Grade 4 treatment-related adverse events were reported in the trial.

Novartis’ Phase III prostate cancer therapy trial meets primary endpoint

Assessing overall survival, which is the crucial secondary endpoint of the trial, is progressing.

Managing drug shortages: Getting medicines to patients in need

Patients around the world are experiencing drug shortages, with production still recovering from the disruption caused by Covid-19, the war in Ukraine, and rising energy costs. Tanner Pharma is tackling these issues head-on, managing disruptions and ensuring that a range of treatments reach patients wherever they are.

Pipeline Moves: Novartis completes ulcerative colitis trial, advancement prospects rise

The Clinical Trials Arena team also reviews assets in oncology, paediatric hormone deficiency, diabetic pain and ophthalmology.

Study shows high prevalence of hypertension among Indian children and teens

Diagnosed cases of hypertension in adults in India are expected to grow from nearly 113 million to more than 121 million by 2027.

Vanda reports data from Phase II acute performance anxiety therapy trial

The study assessed the efficacy and safety of VQW-765 in performance anxiety patients.

Innovent begins subject dosing in Phase I study of orismilast

The study will assess orismilast’s safety, tolerability, and pharmacokinetic profile in healthy Chinese participants.

UroGen reports data from Phase IIb trial of bladder cancer treatment

In the trial, UGN-102 offered a median duration of response of 24.4 months in study subjects.

Vaxxinity’s Phase III Covid-19 booster trial meets endpoints

In the trial, the UB-612 vaccine was generally well tolerated, without any serious adverse events occurring.

Catalent expands clinical supply facility in China’s FTZ

The two facilities provide optimised supply solutions to sponsors for clinical trials that are being undertaken in China.

First patient dosed in Compass Therapeutics’ Phase Ib solid tumour trial

CTX-471 attaches to the CD137 receptor’s membrane proximal epitope, leading to improved activation of T-Cells and NK Cells.

IGC starts clinical trial of drug candidate to treat agitation in dementia

The objective of the trial is to establish IGC-AD1’s efficacy in helping dementia patients reduce neuropsychiatric symptoms.

Curebase and Redenlab to partner for data capture capabilities expansion

The analytical component provides researchers with a comprehensive monitoring approach in trials.

How to cut drug supply costs with seamless forecasting and IRT systems

Cut drug wastage, reduce risk, and optimise supply with advanced, integrated technologies designed to deliver increased visibility, flexibility and accuracy.